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Abstract
Influenza poses a persistent worldwide threat to the human population. As evidenced by the 2009 H1N1 pandemic, current
vaccine technologies are unable to respond rapidly to this constantly diverging pathogen. We tested the utility of
adenovirus (Ad) vaccines expressing centralized consensus influenza antigens. Ad vaccines were produced within 2 months
and protected against influenza in mice within 3 days of vaccination. Ad vaccines were able to protect at doses as low as 107
virus particles/kg indicating that approximately 1,000 human doses could be rapidly generated from standard Ad
preparations. To generate broadly cross-reactive immune responses, centralized consensus antigens were constructed
against H1 influenza and against H1 through H5 influenza. Twenty full-length H1 HA sequences representing the main
branches of the H1 HA phylogenetic tree were used to create a synthetic centralized gene, HA1-con. HA1-con minimizes the
degree of sequence dissimilarity between the vaccine and existing circulating viruses. The centralized H1 gene, HA1-con,
induced stronger immune responses and better protection against mismatched virus challenges as compared to two
wildtype H1 genes. HA1-con protected against three genetically diverse lethal influenza challenges. When mice were
challenged with 1934 influenza A/PR/8/34, HA1-con protected 100% of mice while vaccine generated from 2009 A/TX/05/09
only protected 40%. Vaccination with 1934 A/PR/8/34 and 2009 A/TX/05/09 protected 60% and 20% against 1947 influenza
A/FM/1/47, respectively, whereas 80% of mice vaccinated with HA1-con were protected. Notably, 80% of mice challenged
with 2009 swine flu isolate A/California/4/09 were protected by HA1-con vaccination. These data show that HA1-con in Ad
has potential as a rapid and universal vaccine for H1N1 influenza viruses.
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Introduction
Annually, 5 – 15% of the world’s population is affected by
influenza epidemics and have upper respiratory tract infections, 3
to 5 million have severe illness and 250,000 to 500,000 cases result
in death [1]. While these normal infections are certainly of
concern, natural pandemic influenza outbreaks and intentional
releases of pathogenic influenza are of substantially higher
concern. A difficult obstacle inherent to current trivalent
inactivated vaccine (TIV) production stems from the need to
screen and predict which viruses may circulate in the subsequent
year. These predictions do not always accurately identify the
actual viruses that cause disease that year [2,3,4]. In fact, vaccine
mismatches occurred in 4 out of 8 (50%) flu seasons in the USA
between 1997 and 2005 [5,6,7,8]. In addition to this problem,
some of the immunologic effects of TIV reduces its efficacy. For
example, the current vaccine only provides short-term immunity
[9], the induced immunity is highly strain specific [3,10],
intramuscular delivery does not stimulate high levels of the
secretory IgA that is less specific and is more reactive against
heterologous viruses [10,11,12,13,14], and fail to induce cross-
protective cellular immunity [15,16,17,18,19].
In addition to influenza virus based vaccines, alternative
approaches have been investigated. These include the use of
electroporated DNA expression plasmids, adenovirus vectored
vaccines, and universal vaccines based on centralized genes and
conserved matrix ectodomains [20,21,22,23,24]. Centralized
genes were first proposed as universal vaccines for HIV
[25,26,27,28,29,30]. Centralized sequences minimize the degree
of dissimilarity between a vaccine strain and contemporary
circulating viruses by creating an artificial sequence based on the
most common amino acid in each position in an alignment. Other
than HIV, centralized genes have also been proposed as universal
vaccines for highly pathogenic (H5N1) avian influenza (HPAI) and
Chikungunya virus [20,31,32].
Recently, swine flu was declared a pandemic. Even with the
latest technologies the CDC and the WHO were not able to agree
on a vaccine strategy and implement vaccine production in time
for the 2009–2010 influenza season [33]. Due to the delay in
vaccine availability, the CDC has estimated that between April
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and November 19th 2009 there were between 34 and 67 million
cases of 2009 H1N1, 154,000 and 303,000 2009 H1N1-related
hospitalizations, and 7,070 and 13,930 2009 H1N1-related deaths
[34]. 2009 H1N1 has also been confirmed in more than 276
pediatric deaths to date. More than double the annual seasonal flu
pediatric deaths [34].
To address the issue of pandemic H1N1 influenza virus, we
created a centralized H1 HA immunogen. When in vitro immune
correlates of protection and in vivo prophylaxis was compared. We
found that the centralized H1 antigen, HA1-con, induced greater
and broader immune correlates as compared to two wildtype H1
antigens. We also found that in the case of vaccine mismatch HA1-
con could induce more potent protection against lethal wildtype
influenza challenges. Based on these data, this strategy may be
applicable to the more divergent H1N1 influenza viruses and
represents an alternative universal vaccine that could be either
Figure 1. Phylogenetic trees showing the wildtype genetic relationship of wildtype and consensus HA genes. Selected full-length H1
HA sequences were downloaded from NCBI and aligned using Clustal W. The 566 amino acid consensus sequences was determined from this
alignment. The HA 1–5 con gene is shown localized to the central region of the multi-subtype phylogenetic tree (A). The HA1-con gene is shown in
the phylogenetic H1 subtype tree (B). Unrooted phylogenetic trees were created using PHYLIP version 3.5c. The boxes represent consensus genes
used to create the adenovirus vaccines. Diamonds represent wildtype gene used to create adenovirus vaccines. The circles represent viruses or
peptides used to evaluate in vitro immune correlates induced by the vaccines. Dashed lines represent viruses used in lethal challenges.
doi:10.1371/journal.pone.0018314.g001
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stockpiled or included in the current vaccine formulations in the
case of H1 seasonal or pandemic mismatch.
Materials and Methods
Alignment, Consensus, and Tree Construction
Influenza sequence databases contain a tremendous amount of
sequence information. There are over 30,000 HA sequences
available through Genbank. Although valuable, not all of this
information can be used to create a consensus sequence. During
pandemics, epidemics and endemics there is a renewed interest in
influenza evolution. At these times multiple nearly identical
influenza sequences are entered into the databases from specific
institutions diluting out more divergent, but less sequenced
isolates. Therefore a consensus sequence created using all of the
available sequence information would bias the consensus sequence
to that of the most sequenced isolates and those closely genetically
related. To reduce this bias, we selected twenty full-length H1 HA
sequences from the larger sequence space to represent the main
branches of the H1. (accessions: ISDN13422, CY001952,
CY003833, CY002392, CY006363, CY007467, CY002624,
CY003384, CY003304, CY003696, AF386780, AF386775,
AY289928, AF386774, D13574, X17221, U02085, M38312,
S62154, and U53162). Novel 2009 H1N1 HA genes were not
included in the initial H1 HA consensus design because they had
not been identified at the time of analysis. Selected full-length H1
HA sequences were downloaded from Genbank and aligned using
Clustal W. All aligned sequences were then inspected manually to
correct for apparent mistakes. Positions containing gaps or
ambiguously aligned positions were removed from the datasets.
The 566 amino acid consensus sequence, named HA1-con, was
generated from this alignment by using the most common amino
acid at each position. Unrooted phylogenetic trees were created
using PHYLIP version 3.5c (Figure 1B). The HA 1–5 consensus
gene, HA 1–5 con, was created by the same strategy with the
exception that sequences from H1, H2, H3 and H5 were used
(Figure 1A) (accessions: D13574, S62154, U02085, NC_002017,
CY002624, CY006363, AF386775, AF386780, AY289928,
ISDN13422, CY003833, CY002392, CY003384, CY007467,
CY003696, AY209963, AY209961, L20409, L11134, D13579,
L11126, L11142, L20406, L11125, M54895, AJ289703, V01103,
CY006044, CY003064, M55059, CY002056, DQ249261,
CY000137, CY002136, AY032978, AB019357, CY002088,
X05907, CY002072, CY002904, AJ252131, CY000017,
CY003512, CY002744, CY002496, ISDN121986, AB239125,
DQ372591, ISDN119678, ISDN117778, ISDN117777,
ISDN118371, AJ867074, ISDN110940, AY555150, ISDN40341,
AY651334, AY651335, ISDN40278, AY575869, AY575870,
ISDN38262, AF102676, AF084279, AF046097, AF084280, and
AF084532). N and O linked glycosylation sites for the vaccine
genes HA1-con, A/PR/8/34, and A/TX/05/09 were analyzed
using NetNGlyc 1.0 and NetOGly 3.1 software analyses.
Viruses and Vaccines
Influenza virus A/PR/8/34 was obtained from ATCC (VR95).
Influenza viruses A/Denver/1/57, A/Fort Monmouth/1/47, A/
Texas/36/91, and A/NWS/33 were obtained from the Biode-
fense and Emerging Infections Research Resources Repository. All
of the viruses were passaged one time in SPF embryonated eggs
and the chorioallantoic fluid was stored at 280C. The pandemic
H1N1 virus used in challenge studies was a mouse-adapted A/
California/04/09 virus. This virus was adapted for lethality in
mice through serial lung passage as previously described [35].
Stocks of virus were grown in embryonated eggs and the
chorioallantoic fluid was stored at -80C).
The influenza virus A/PR/8/34 and A/FM/1/47 stock was
titered in BALB/c mice to determine its 50% mouse lethal dose
(MLD50). The HA sequences for A/PR/8/34, A/TX/05/09 A/
HK/213/03 were obtained from NCBI and the Influenza
Sequence Database at Los Alamos National Laboratories,
respectively. HA1-con, HA 1–5 con, A/PR/8/34, A/TX/05/
09, and A/HK/213/03 HA genes were codon-optimized for
mammalian expression and synthesized by Genscript. Inc. First
generation replication defective (E1/E3 deleted) Ad5 vectors were
constructed using the Ad-Easy system in 293A cells as described in
[36]. All adenoviruses were purified by CsCl banding and
quantitated by OD260. The recombinant Adenoviruses expressing
A/PR/8/34, A/TX/05/09, A/HK/213/03, HA1-con and HA1-
5 con were named Ad-PR-HA, Ad-TX-HA Ad-HK-HA, Ad-
HA1-con, and Ad-HA-1-5-con, respectively. The infectivity of the
recombinant adenoviruses was checked using the Adeno-X Rapid
titer. There were no statistical differences in infectivity (Figure S1).
All virus stocks were found to contain #0.1% replication
competent adenovirus.
Animals
Female BALB/c mice (6–8 weeks old) were purchased from
Charles River Laboratories (Wilmington, Massachusetts, USA)
and housed in the Mayo Clinic or St Jude Children’s Research
Hospital Animal Facility under the Association for Assessment and
Accreditation of Laboratory Animal Care (AALAC) guidelines
with animal use protocols approved by the corresponding the
Mayo Clinic Institutional Animal Care and Use Committee
(IACUC protocol No. A110). All animal experiments were carried
out according to the provisions of the Animal Welfare Act, PHS
Animal Welfare Policy, the principles of the NIH Guide for the
Care and Use of Laboratory Animals, and the policies and
procedures of Mayo Clinic and St Jude Children’s Research
Hospital.
Mice were anesthetized i.p. with ketamine (140 mg/kg)/
kylazine (5.55 mg/kg) and were immunized intramuscularly
(i.m.) with various doses of Adenovirus in a volume of 50 ul.
Twenty-five ml was injected into each mouse quadriceps. Three
weeks post-immunization the mice were challenged intranasally
with mouse-adapted influenza virus A/PR/8/34, A/FM/1/47, or
A/California/04/09.
Cellular Immunity: Enzyme-Linked Spot (ELISPOT) Assay
Mice were immunized i.m. with 1010 virus particles (vp) of
adenovirus expressing HA genes from PR, TX or H1 consensus.
Three weeks post-immunization the mice were sacrificed and
spleens were harvested. ELSIPOT assays were performed as
previously described [37]. Overall cellular immune responses were
measured using three pools of a peptide array, Influenza Virus A/
New Caledonia/20/99 (H1N1) Hemagglutinin Protein. The
peptides consisted of 94 16- to 17-mers, with 11 or 12 amino
acid overlaps and were obtained from the Biodefense and
Emerging Infections Research Resources Repository (Catalog
No. NR-2602). Then using a matrix of peptide pools and
individual peptides the immuno-stimulatory epitopes were
mapped. Concanavalin A (5 mg/ml) was used as a positive control
while splenocytes from DPBS immunized animals as well as media
only wells were used as negative controls. Responses were
considered as positive if the number of the spots was four-fold
higher than that of the negative control and at least 50 SFC/106
cells.
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Humoral Immunity: Hemaglutination Inhibition (HI)
Assay
Mice were immunized i.m. with 1010 vp of adenovirus
expressing HA genes from PR, TX or H1 consensus. Three
weeks post-immunization the mice were bled by cardiac puncture
and sacrificed. Serum was collected using Becton Dickinson
microtainer tubes with serum separator. Starting at a dilution of
1:5 sera were diluted two-fold in 50 ml of DPBS in a 96-well,
nonsterile, nontissue culture–treated, round bottom microtiter
plate. Four HAU of influenza virus in 50 ul was added to the
diluted sera and incubated at room temperature (RT) for 1 hr.
After incubation, 50 ml of a 1% chicken RBC solution was added
and incubated at RT for 1 hr. The HI titer was determined to be
the highest serum dilution to inhibit hemagglutination.
Influenza Challenge
Mice were immunized with various doses of the Ad-vectored
vaccines. Three weeks after immunization the mice were
anesthetized i.p. with ketamine (140 mg/kg)/xylazine (5.55 mg/
kg). The mice were weighed for baseline measurements. The mice
were challenged intranasally with 100LD50 of influenza A/PR/8/
34 or A/FM/1/47 virus or 70LD50 of A/California/04/09 virus.
The mice were placed on their backs and 10 ml of A/PR/8/34 or
A/FM/1/47 virus was pipetted into each nare for a total volume
of 20 ml. For infection with A/California/04/09, 15 ml was
delivered to each nare for a total of 30 ml. The mice were then
weighed and monitored daily for signs of disease. Mice were
humanely euthanized if their body weight dropped to 75% of
baseline weights.
Results
Production of Centralized Consensus HA Immunogens
A comparison of select H1 hemagglutinin (HA) protein
sequences from 1933 through 2009 generated a phylogenetic tree
with ,21.0% of sequence divergence across the branches
(Figure 1B). Due to high levels of genetic diversity, selecting a
single wildtype HA protein as a universal vaccine is not thought to
be feasible. Rather than select one wildtype gene as a vaccine, we
generated a centralized gene that mimics an ancestor of influenza
infections during the past 76 years. The rationale for this approach
is to produce an immunogen that is centrally located with respect
to all other variants. Such a protein then practically has lower
sequence divergence with all of the variants than any two
randomly selected genes.
Phylogenetic analysis shows that the synthetic centralized HA1-
con protein localizes to the central region of the H1 tree
(Figure 1B). When genetic distances were calculated using
ClustalW, the HA1-con was found to be half the genetic distance
to the wildtype influenza strains used in this study (Table 1). For
example, influenza A/FM/1/47 was used as a challenge strain in
subsequent studies using three homologous vaccines, HA1-con, A/
TX/05/09 and A/PR/8/34. When the genetic distances from the
mismatched vaccines to the challenge strain were calculated, the
HA1-con was closest genetically with 4.8% divergence. A/TX/
05/09 and A/PR/8/34 were found to be 19.6% and 9.7%
divergent, respectively (Table 1). When vaccinated mice were
challenged with A/PR/8/34 the mismatched vaccines HA1-con
and A/TX/05/09 were 8.5% and 18.6% divergent, respectively.
Again, HA1-con is closest genetically when the vaccine and
challenge strain are mismatched. Although HA1-con was not half
the genetic distance to the A/CA/04/09 flu challenge strain as
compared to the mismatched A/PR/8/34, it was slightly closer
(Table 1).
Alignment of HA amino acid sequences showed that the HA1-
con protein conserved functional elements that include cleavage,
fusion, transmembrane and cytoplasmic domains (Figure 2).
Comparison of predicted N and O linked glycosylation sites for
HA1-con to HAs from A/PR/8/34 and A/TX/05/09 indicated
that all of the N-glycosylation sites for A/TX/05/09 and A/PR/
8/34 were present in HA1-con (Figure 2). In addition, there were
two additional potential N-glycosylation sites in the HA1-con at
positions 144 and 201. The predicted N-glycosylation at position
144 was also found in several other isolates such as A/FM/1/47
and A/CHR/157/83. The predicted N-glycosylation at position
201 in HA1-con was not present in the subset of HA proteins
analyzed, but represents a conserved asparagine sequence from
the 20 HA proteins used for construction. No O-glycosylation was
predicted in HA1-con, A/PR/8/34, or A/TX/05/09 (Figure 2).
A broader HA consensus protein (HA 1–5 con) was engineered
as a centralized immunogen spanning H1, H2, H3, H4, and H5
influenza viruses (Figure 1A). Although H4 influenza infections
have yet to be discovered in humans, it was included in the tree
construction to illustrate that the HA 1–5 con gene localizes
centrally to this subtype as well. Influenza has a tremendous
amount of evolutionary plasticity in its HA sequences as H3 and
H5 proteins, for example, are as much as 60% divergent
(Figure 1A). A blast search of the Genbank viral sequences
database of the HA 1–5 con protein sequence revealed the closest
influenza isolates had only 69% identity. All of the closest isolates
were H1N1 viruses and included A/SouthCarolina/1/1918
(H1N1), A/swine/Jamesburg/1942 (H1N1), A/swine/Iowa/
1945 (H1N1), and A/duck/Italy/281904/2006 (H1N1). Table 1
shows that the genetic distance between HA 1–5 con and all of
selected H1 isolates is equally distant from them as the H5
influenza virus A/Hong Kong/213/2003 (A/HK/213/03). Based
on conventional wisdom, the amino acid divergence of this
synthetic HA 1–5 con gene would not be predicted to induce
Table 1. Clustal Distance Matrix.
A/FM/1/47 A/NWS/33 A/TX/36/91 A/Denver/1/57
A/New Caledonia
/20/99 A/PR/8/34 A/CA/04/09
A/PR/8/34 0.097 0.078 0.122 0.115 0.126 0.000 0.186
A/TX/05/09 0.196 0.182 0.208 0.202 0.202 0.186 0.005
A/HK/213/03 0.374 0.362 0.369 0.317 0.368 0.355 0.371
HA1-con 0.048 0.083 0.055 0.078 0.059 0.085 0.173
HA 1–5 con 0.317 0.313 0.313 0.366 0.306 0.315 0.318
Distance matrix calculated using ClustalW with no exclusions of positions with gaps and no correction for multiple substitutions.
doi:10.1371/journal.pone.0018314.t001
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protection against H1 influenzas. Based on this, a codon-
optimized gene for HA 1–5-con was constructed and used to
generate the vaccine Ad HA 1–5-con. This vector was included as
a divergent immunogen to act as a likely negative control for the
HA1-con vaccine, but also as a long-shot cross-reactive vaccine
against many influenza viruses.
Intrasubtype Protection at High Doses of Vaccine
Mice were immunized with 1010 virus particles (vp) of all of the Ad
influenza vaccines. Three weeks later, the immunized mice received
a lethal challenge with one hundred times the mean lethal dose (100
LD50) of influenza A/PR/8/34 virus (Figure 3A). Only HA1-con
and the cognate immunogen A/PR/8/34 HA were able to protect
mice from disease, weight loss, and death. A/TX/05/09 HA was
able to protect the mice from death. However, there were still signs
of disease and weight loss using a large dose of vaccine. As predicted
the other vaccines were unable to protect against disease and death.
Protection Against Homologous Challenge at Low Dose
Direct comparison of gene-based vaccines in non-human
primates has demonstrated that Ad vaccines generate more robust
immune responses and protection than plasmid or vaccinia
vaccines [38]. Given our goal to develop a gene-based vaccine
for influenza, we tested this vaccine platform by inserting the
codon-optimized cDNA for HA from H1 influenza A/Puerto
Rico/8/1934 (A/PR/8/34) into a E1-deleted replication-defective
Ad5 vector (Ad-PR-HA). To titrate the efficacy of the vaccine,
groups of 5 female BALB/c mice were immunized with a range of
doses of Ad-PR-HA by the intramuscular (i.m.) route and were
challenged 3 weeks later with 100 LD50 of influenza A/PR/8/34
(Figure 3B). A vaccine dose of 107 vp was capable of completely
protecting mice from death and disease. An even lower dose of 106
vp demonstrated reduced weight loss and increased survival
against this stringent lethal challenge.
Rapid Protection Against Stringent Lethal Challenge
Ad vectors produce rapid and high levels of protein production
in vivo [39]. To assess the kinetics of Ad vaccine protection, groups
of 5 BALB/c mice were vaccinated with 1010 vp of Ad-PR-HA by
the i.m. route and then challenged with 100 LD50 of A/PR/8/34
influenza 1, 3, or 5 days after vaccination (Figure 3C). Under these
conditions, mice were fully protected from this challenge within 5
days of vaccination. In addition, mice vaccinated 3 days before
challenge showed clinical signs of disease and weight loss, but most
survived this stringent challenge. These data suggest that Ad
vaccines may generate rapid protection against influenza.
Cross-reactive Cellular Immune Responses
Three weeks after i.m. immunization with 1010 vp of recombi-
nant adenovirus, the mice were sacrificed and splenocytes were
harvested for ELISPOT assays (Figure 4A and B). Splenocytes were
stimulated with overlapping peptides from the heterologous virus
A/New Caledonia/20/99 (Figure S2). Both A/PR/8/34 and HA1-
con immunized mice induced significantly greater cellular immune
responses than A/TX/05/09 immunized mice with p values of
0.026 and 0.001, respectively (Figure 4A). Individual immunosti-
mulatory peptides were identified using overlapping peptide pools
and individual peptides (Figure 4B). Greater than 50 interferon-c
spot-forming cells (SFC) were considered significant. Epitope
mapping revealed that five epitopes (6, 21/22, 31, 78 and 90) were
recognized by splenocytes from the immunized mice (Figure 4B).
HA1-con generated greater T cell responses against all peptides
than either A/PR/8/34 or A/TX/05/09 with the only exception
being against peptide 6. T cells from HA1-con immunized mice
reacted against two dominant epitopes 78 and 90 while A/PR/8/34
only induced one dominant T cell response against epitope 90. In
addition HA1-con immunized mice induced T cell responses
against epitope 31 while A/PR/8/34 and A/TX/05/09 immu-
nized mice did not. Interestingly, almost all of these epitopes were
entirely conserved in all of the genes (Figure S2). There were two
amino acid substitutions in epitope 31 that were not in HA1-con.
HA1-con immunized mice induce much stronger T cell immune
responses against epitope 78, however there were no sequence
differences between the HA1-con and A/PR/8/34 and A/TX/05/
09 at that site.
Cross-reactive Humoral Immune Responses
Groups of 10 BALB/c were immunized with 1010 vp of Ad
vaccine. Three weeks after immunization, sera from the mice were
tested for hemagglutination inhibition (HI) antibody responses
against a series of wildtype H1 influenza viruses (Figure 4C). HA1-
con induced HI titers that were equal or greater than those
induced by A/PR/8/34 or A/TX/05/09 against isolates A/FM/
1/47, A/TX/36/1991 and A/NWS/33. HA1-con immunized
mice generated significantly higher HI titers against A/FM/1/47
influenza than A/PR/8/34 (p =,0.001). HA1-con induced
significantly greater HI titers against A/FM/1/47 and A/NWS/
33 viruses than A/TX/05/09 (p =,0.001). However, A/TX/05/
09 did induce significantly higher HI titers against A/Denver/1/
57 than both Ad-PR-HA and Ad-HA1-con (p=,0.001). Values
were log transformed for statistical analyses.
Protection Against Lethal A/PR/8/34 Influenza
As expected the homologous A/PR/8/34 vaccine was able to
induce protective responses using the lowest dose of vaccine as
compared to the mismatched vaccines, HA1-con and A/TX.05/
09 (Figure 5). A/PR/8/34 immunized mice did not show any
signs of disease or death with doses as low as 107 vp (Figure 5).
Immunization with 106 vp did not prevent disease, but did provide
protection against disease in 75% of mice. Doses lower than 106 vp
resulted in disease and death (Figure S3). In regard to the vaccine
mismatches, the HA1-con was able to protect against disease at a
dose of 108 vp while A/TX/05/09 vaccinated mice exhibited
signs of disease and weight loss. Both HA1-con and A/TX/05/09
were able to protect against death at a dose of 108 vp. Mice
vaccinated with HA1-con at a dose of 107 vp did show signs of
disease and weight loss. However, these mice recovered and
survived the challenge whereas 60% of mice vaccinated with A/
TX/05/09 at the same dose did not survive (Fig 5) (p = 0.05).
Doses lower than 107 vp resulted in disease and death (Figure S3).
Protection Against Lethal A/FM/1/47 Influenza
In contrast to the homologous A/PR/8/34 virus challenge, A/
PR/8/34 HA was not able to induce protection from disease and
death from lethal A/FM/1/47 at a dose of 107 vp (Figure 6). In
fact, doses up to 109 vp of Ad-PR-HA were unable to prevent
Figure 2. Alignment of the centralized influenza vaccine genes, the wildtype virus genes and the A/New Caledonia/20/99 HA
proteins showing the location and sequence of the major antigenic sites Sa, Sb, Ca and Cb. The conserved functional elements consisting
of the secretory signal, cleavage, fusion, transmembrane and cytoplasmic tail are indicated and boxed. N-linked glycosylation sites (Gly) are shown
boxed in yellow.
doi:10.1371/journal.pone.0018314.g002
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Figure 3. Adenovirus as a platform for Influenza vaccines. Prophylactic responses in mice immunized with consensus and wildtype adenoviral
vectors were determined by immunizing mice with 1010 Ad vaccine viral particles. Three weeks after immunization the mice were challenged
intranasally with 100 MLD50 of influenza A/PR/8/34 virus (A). In order to determine how much ad vaccine would be required to induce prophylaxis,
mice were immunized intramuscularly with 10-fold dilutions of adenovirus expressing the A/PR/8/34 HA and challenged with 100 MLD50 of influenza
A/PR/8/34 virus 3 weeks later (B). In order to determine the length of time to induce prophylaxis and the duration of prophylactic immune responses
using Ad vaccines, mice were immunized intramuscularly with 1010 vp of Ad expressing A/PR/8/34 HA. The mice were challenged intranasally with
100 MLD50 of influenza A/PR/8/34 virus 1, 3, 5 and 200 days post immunization (C). Weight loss and survival were monitored daily. Mice that lost more
than 25% of their baseline weight were humanely sacrificed.
doi:10.1371/journal.pone.0018314.g003
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disease and weight loss (Figure S4). The mismatched A/TX/05/
09 vaccine was even less effective at inducing protective responses
against the influenza A/FM/1/47 virus lethal challenge. Doses of
109 vp of A/TX/05/09 were unable to protect against death.
However, Ad-HA1-con was able to induce protection against
weight loss at a dose of 109 vp (Figure S4). Vaccination with a dose
of 108 vp of HA1-con provided the best protection against weight
loss and death (Figure 6). Both HA1-con and A/PR/8/34
protected against death while A/TX/05/09 did not resulting in
only 60% survival. A lower dose, 107 vp, resulted in weight loss
and death in all groups, however, the HA1-con group were best
protected resulting in less average weight loss and the best survival
(Figure 6). Mice immunized with 107 vp of HA1-con resulted in
80% protection against death whereas only 20% of A/TX.05/09
immunized mice were protected from death (p = 0.06). Doses
lower than 107 vp resulted in significant weight loss and death in
all groups. However, the only mouse to survive after immunization
with 106 vp was in the HA1-con group (Figure S4).
Protection Against Lethal A/California/04/09
As predicted the A/TX/05/09 vaccine provided the best levels
of protection against a lethal challenge with A/CA/04/09
(Figure 7). Similarly, A/TX/05/09 protected against death at a
dose of 107 vp and provided some protection at a dose of 106 vp as
did A/PR/8/34 against a homologous lethal challenge. A/TX/
05/09 vaccine provided complete protection against weight loss
and disease at a dose of 108 vp (Figure S5). When the vaccines
were mismatched, the centralized HA1-con proved to be better at
inducing protective immunity as compared to A/PR/8/34
(Figure 7). At higher doses HA1-con vaccinated mice showed less
average weight loss and were better protected against death than
A/PR/8/34 vaccinated mice resulting in 80% and 20% survival,
respectively. While there were no significant differences in survival
between mice immunized with 1010 vp of either HA1-con or A/
TX/05/09, there were significant differences between A/TX/05/
09 and A/PR/8/34 survival rates (p = 0.01). At a dose of 109 vp
60% of HA1-con vaccinated mice survived while only 20% of A/
PR/8/34 vaccinated mice survived (Figure 7). There were no
statistical differences in survival between mice immunized with 109
vp of A/TX/05/09 or HA1-con. However, A/PR/8/34 ad A/
TX/05/09 immunized mice did have significantly different
survival rates (p = 0.01). All doses lower than 109 vp of mismatched
vaccine resulted in death (Figure S5).
Discussion
We tested a centralized gene for use as a universal vaccine
against H1N1 influenza viruses that might be relevant to seasonal
and pandemic influenza. Phylogenetic analysis of HA1-con
showed that it did localize to the central region of the phylogenetic
tree and was, for the most part, genetically equidistant to the
majority of wildtype isolates. In vitro characterization showed that
an adenoviral vectored HA1-con gene could induce immune
correlates in mice equal to or greater than that induced by
wildtype genes. Results from the ELISPOT assay indicates that
HA1-con induces stronger and broader T cell immune responses
in splenocytes. While these cellular immune responses are the
primary means by which an influenza viral infection is cleared
they are not essential to prevent infection. Humoral immune
responses as measured by the HI assay indicate that HA1-con
could induce protective responses against all four wildtype isolates
tested, providing that the standard measure of protection is an HI
titer of 40 or higher [40]. The immune correlates presented here
are limited. Intranasal IgA and lung cellular immune responses are
Figure 4. Immune correlates of Protection. Mice were immunized
with 1010 Ad vaccine viral particles. Three weeks post-immunization the
mice were bled and spleens were removed for anti-influenza humoral
and cellular responses. Splenocytes were stimulated with peptide pools
representing full-length A/New Caledonia/20/99 HA protein in order to
determine the overall magnitude of wildtype cellular immune
responses (A). Individual peptides were used to identify specific
epitopes recognized by splenocytes from immunized mice. The peptide
numbers that resulted in positive cellular responses are shown (B).
Hemagglutination inhibition (HI) titers induced by the vaccine genes
against wildtype viral isolates (C). Groups of 5 mice were used and error
bars represent standard error.
doi:10.1371/journal.pone.0018314.g004
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Figure 5. Protection against A/PR/8/34 influenza virus infection. Mice were immunized intramuscularly with various doses of A/PR/8/34, Ad-
HA1-con, and A/TX/05/09 HA expressing virus. Three weeks after immunization the mice were challenged intranasally with 100 LD50 of influenza virus
A/PR/8/34. Individual mouse weights for the vaccinated mice and the mean and standard error of the control DPBS immunized mice are shown. Mice
exhibiting profound signs of disease and less than 75% of baseline weights were humanely sacrificed.
doi:10.1371/journal.pone.0018314.g005
Figure 6. Protection against A/FM/1/47 influenza virus infection. Mice were immunized intramuscularly with various doses of A/PR/8/34, Ad-
HA1-con, and A/TX/05/09 HA expressing virus. Three weeks after immunization the mice were challenged intranasally with 100 LD50 of influenza virus
A/FM/1/47. Individual mouse weights for the vaccinated mice and the mean and standard error of the control DPBS immunized mice are shown. Mice
exhibiting profound signs of disease and less than 75% of baseline weights were humanely sacrificed.
doi:10.1371/journal.pone.0018314.g006
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also critical immune correlates of protection. However, since we
planned to evaluate the vaccine-induced immune responses using
a virus challenge advanced immune assays were not necessary.
Also, the dose used for this initial evaluation was considerable and
would not be practical if scaled up for use in humans.
The ultimate proof of a better vaccine lies in the data from the
challenge studies. Not only did the HA1-con centralized gene
induce protective responses against all three H1N1 lethal
challenges, it was a superior vaccine as compared to all other
mismatch vaccines. Although HA1-con did provide better
protection against A/California/04/09 than the mismatched A/
PR/8/34, these protective responses were at high doses of vaccine.
However, these studies were done using high doses of pathogenic
influenza virus. The use of 100 LD50 is not representative of any
epidemic or pandemic ever recorded. Therefore, protective
responses against infectious, but not lethal influenza virus may
be achieved with even lower doses of adenovirus vectored
vaccines. It was surprising to find that matched Ad vectored
vaccines provided protection against a very stringent lethal
challenge at very low doses. Doses as low as 106 vp of Ad
(46107 vp/kg) reduced weight loss and increased survival against
stringent lethal challenge. Extrapolation of this vaccine dose to a
70 kg human suggests that Ad vaccine production from a simple
cell factory of 109 cells would produce as many as 1,000 estimated
human doses of influenza vaccine. Given that it requires up to 3
eggs to produce one human dose of current trivalent vaccine, this
suggests that Ad may be a viable platform for human vaccines.
This combined with the observed rapid protection within 5 days of
immunization make Ad an attractive influenza vaccine platform to
combat seasonal and epidemic spread of influenza.
Another interesting aspect of this study was the creation and
testing of a multi-subtype centralized gene, HA 1-5 con. One of
the attractive qualities of a centralized immunogen is that
conserved or ‘‘shared’’ regions or epitopes would be incorporated
into the gene. However, it could be that in the case of high levels of
divergence (i.e. inter-subtype) these conserved epitopes would be
lost. From a viral evolution standpoint it is interesting that there do
not appear to be intermediate HA sequences found in nature that
are similar to the centralized HA 1-5 con. However, within the
subtypes there are naturally occurring sequences that are similar to
HA1-con. In addition to the absence of viral intermediates similar
to the HA 1-5 con gene, it is at least ,30% divergent from all
reported wildtype isolates. Given H5 and H1 genes are similarly
divergent and that H5 genes do not protect against H1 wildtype
virus, it is very possible that HA 1-5 con may simply act as a
control HA gene for further studies.
Although the centralized influenza genes proposed in this study
are for use as human vaccines, the same concepts and perhaps the
same genes may be used to vaccinate reservoir animals against
influenza infections. Vaccination of reservoir animals at the source
of virus evolution could intervene at this primary step and could
result in the elimination of potential future influenza outbreaks
that result in pandemics. To this end, our Ad virus vector platform
may also be applicable in this approach and may prove to be more
potent and cost-effective than traditional vaccines.
While previous studies have reported on the efficacy of
consensus H5 genes conferring protection against wildtype
influenza virus infection, this is the first reported study that has
applied this concept to the more diverse H1 subtype. Here we
show that HA1-con is a superior vaccine in the case of mismatch
only and produced equal or greater cross-protective immune
correlates against wildtype viruses as compared to wildtype HA
gene vaccines. However, in the case of a matched vaccine the
homologous vaccine gene is superior to HA1-con. For example,
Figure 7. Protection against A/CA/04/09 influenza virus infection. Mice were immunized intramuscularly with various doses of A/PR/8/34,
Ad-HA1-con, and A/TX/05/09 HA expressing virus. Three weeks after immunization the mice were challenged intranasally with 70 LD50 of influenza
virus of A/CA/04/09. Individual mouse weights for the vaccinated mice and the mean and standard error of the control DPBS immunized mice are
shown. Mice exhibiting profound signs of disease and less than 75% of baseline weights were humanely sacrificed.
doi:10.1371/journal.pone.0018314.g007
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Ad-PR induces superior levels of protection against A/PR/8/34
virus as compared to the centralized HA1-con.These data support
the concept of using consensus genes as influenza vaccines either
as single vaccines or as a ‘‘platform’’ gene to provide broad
immunologic cross-reactivity for combination with other single
isolate influenza genes.
Supporting Information
Figure S1 In order to determine the quality of the
adenoviral vectors being used the infectivity of the preps
were analyzed using the AdenoX rapid titer kit. 293 cells
were infected with each of the viral preps incubated overnight and
stained for hexon expression. There were no significant differences
in the Adenoviral vaccine preps.
(TIF)
Figure S2 Alignment of the consensus influenza vaccine
genes, the wildtype virus genes and the A/New Caledo-
nia/20/99 HA proteins. Numbers represent the epitopes
identified in Figure 4. Boxes represent the individual peptides that
were recognized by immunized mice splenocytes. The green box
represents a unique epitope recognized only by Ad-HA1-con
immunized splenocytes and the red box represents the conserved
immunodominant CTL epitope. Groups of 5 mice were used and
error bars represent standard error.
(TIF)
Figure S3 Dose-dependent prophylactic responses
against a lethal A/PR/8/34 influenza virus challenge.
Mice were immunized intramuscularly with various doses of A/
PR/8/34, Ad-HA1-con, and A/TX/05/09 HA expressing virus.
Three weeks after immunization the mice were challenged
intranasally with 100 LD50 of influenza virus A/PR/8/34. Weight
loss and death in mice immunized 106 vp are shown in A and B,
respectively. Weight loss and death in mice immunized 105 vp are
shown in C and D, respectively. The mean and standard error of
the control DPBS immunized mice are shown. Mice exhibiting
profound signs of disease and less than 75% of baseline weights
were humanely sacrificed.
(TIF)
Figure S4 Dose-dependent prophylactic responses
against a lethal A/FM/1/47 influenza virus challenge.
Mice were immunized intramuscularly with various doses of A/
PR/8/34, Ad-HA1-con, and A/TX/05/09 HA expressing virus.
Three weeks after immunization the mice were challenged
intranasally with 100 LD50 of influenza virus A/FM/1/47.
Weight loss and death in mice immunized 10 vp are shown in A
and B, respectively. Weight loss and death in mice immunized 106
vp are shown in C and D, respectively. Weight loss and death in
mice immunized 105 vp are shown in E and F, respectively. The
mean and standard error of the control DPBS immunized mice
are shown. Mice exhibiting profound signs of disease and less than
75% of baseline weights were humanely sacrificed.
(TIF)
Figure S5 Dose-dependent prophylactic responses
against disease after a lethal A/CA/04/09 Swine flu
influenza virus challenge. Mice were immunized intramus-
cularly with various doses of A/PR/8/34, Ad-HA1-con, and A/
TX/05/09 HA expressing virus. Three weeks after immunization
the mice were challenged intranasally with 100 LD50 of influenza
virus 2009 Swine Flu. Weight loss and death in mice immunized
108 vp are shown in A and B, respectively. Weight loss and death
in mice immunized 107 vp are shown in C and D, respectively.
Weight loss and death in mice immunized 106 vp are shown in E
and F, respectively. Weight loss and death in mice immunized 105
vp are shown in G and H, respectively. The mean and standard
error of the control DPBS immunized mice are shown. Mice
exhibiting profound signs of disease and less than 75% of baseline
weights were humanely sacrificed.
(TIF)
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